Adaptive Servo-Ventilation

Alternative Names: ASV, ResMed AirCurve 10 ASV, Philips DreamStation BiPAP autoSV, ResMed AirCurve ASV VAuto

Adaptive Servo-Ventilation (ASV) is an advanced therapy for central sleep apnea, especially effective in treating complex or treatment-emergent CSA and Cheyne-Stokes respiration. It continuously monitors the patient’s breathing and adjusts pressure support breath-by-breath to stabilize ventilation, delivering backup breaths when needed. ASV is typically used when CPAP or BPAP with backup rate fail, but it is contraindicated in patients with symptomatic heart failure and reduced ejection fraction (≤45%) due to increased risk of adverse outcomes.

Treatment Type: Device

Treatment Class: N/A

Treatment Modality: N/A

Adaptive Servo-Ventilation

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the single review provided, Adaptive Servo-Ventilation (ASV) appears to be an effective next-line therapy for central sleep apnea when CPAP or BPAP fail to control symptoms. However, it is important to note that ASV is contraindicated in patients with heart failure and reduced ejection fraction (≤45%).

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
1.0
1 = Very Expensive 5 = Very Affordable

1.0

Very Expensive
Relief Speed
5.0
1 = No Relief 5 = Immediate Relief

5.0

Immediate Relief
Side Effects
3.0
1 = Intolerable Effect 5 = No Effect

3.0

Moderate Effect
Treatment Line
3.0
1 = Third-line or more 5 = First-line

3.0

Second Line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the single review provided, Adaptive Servo-Ventilation (ASV) appears to be an effective next-line therapy for central sleep apnea when CPAP or BPAP fail to control symptoms. However, it is important to note that ASV is contraindicated in patients with heart failure and reduced ejection fraction (≤45%).

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
2 months ago
Adaptive Servo-Ventilation is a next-line therapy for central sleep apnea, typically used when treatments like Continuous Positive Airway Pressure or Bilevel Positive Airway Pressure don’t adequately control symptoms. It works by providing dynamic, breath-by-breath pressure support to stabilize breathing patterns during sleep and reduce central apnea events. Compared with standard positive airway pressure therapies, it has better evidence for improving sleep quality and overall quality of life in appropriate patients. However, it is contraindicated in patients with heart failure and reduced ejection fraction (≤45%), where studies have shown potential harm.
#VeryExpensive #ImmediateRelief #ModerateEffect #Second-line #Maintenance
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All